DiaGen AI Inc. And Metanova Labs Announce Joint Venture LOI To Develop Hit Picking Tool For Automating Drug Discovery

Powered by the Bittensor $TAO Network, DiaGen Ai and Metanova Labs will Leverage Collective Intelligence to Accelerate R&D Toward Faster Commercialization

DiaGen AI Inc. (“DiaGen”, or the Company) founded in 2021, established to advance a diverse pipeline of AI drug discovery tools to scale its asset development and provide solutions through its Ai aS A Partner offering to impact traditional drug discovery, is pleased to announce a milestone driven joint venture LOI (the "JV") with Metanova Labs ("Metanova"), pioneers of crypto-native drug discovery with the world’s first decentralized virtual drug screening platform, NOVA, built on the Bittensor network.

Initial workflows have begun between both teams with the goal to leverage unique data sets to build screening tools for real world drug discovery to score objectives and evaluate AI driven asset development.

The collaboration will integrate DiaGen’s bioinformatic/AI expertise with Metanova’s collective intelligence platform for virtual drug screening. Together, the teams will build a multi-objective hit-picker capable of evaluating small molecules for novelty, affinity, and target specificity across multi-million and billion size libraries, advancing the shared goal of faster, more efficient drug discovery.

“NOVA’s libraries already include over 10 million molecules,” said Micaela Bazo, CEO of Metanova Labs. “This collaboration allows us to automate and scale the way we — and our partners — identify and prioritize the most promising candidates for validation, accelerating the translation of virtual discoveries into real therapeutics.”

Brian D. Keane, Chairman & CEO of DiaGen AI, concurred, “Team DiaGen is excited to work with Micaela and team Metanova, on our continued and now collective goal to leverage novel, decentralized data and intelligence to drive development of AI driven tools for better, faster drug discovery for biologists, chemists and traditional biotech companies. Our initial picking tool is one of many development projects we will tackle together as we scale our JV, so all are incentivized toward real world impact.”

Joint Venture Overview
Initial LOI terms for the joint venture include:

Co-Development:
The companies will jointly develop a target–interaction-based hit-picker tool, integrating experimental data for continuous optimization.

Shared IP & Revenue Model:
The tool and its derivatives will be co-owned. When used for external applications, such as generating token-gated compound libraries for external biotech and pharmaceutical clients, revenues will be shared in agreed proportions reflecting each party’s contribution.

Governance & Next Steps
Both parties agree to form a joint working group to define project milestones, governance structure, and revenue allocation. A formal, definitive JV, co-development agreement will follow successful completion of the prototype and technical validation phase.

For more information, visit www.diagen.ai and www.metanova-labs.ai

About Metanova Labs:
Metanova Labs is a crypto-native biotech company at the forefront of AI-driven drug discovery. Built on the Bittensor ($TAO) network, Metanova created NOVA, the first decentralized virtual screening platform that harnesses global compute and collective intelligence to explore vast, uncharted chemical spaces.

The company’s R&D centers on next-generation therapeutics designed to regulate mental states and restore core biological functions. Metanova’s decentralized approach not only accelerates its own research but also opens access to scalable, collaborative innovation for the broader scientific community.

For more information, visit www.metanova-labs.ai

About DiaGen AI:
Headquartered in Vancouver, DiaGen AI Inc. is developing a diverse pipeline of AI-powered tools for small molecule and peptide discovery, diagnostics, and delivery. Using its proprietary AI engine, DiaGen aims to de-risk, accelerate, and create value across the global traditional drug discovery sector — advancing precision medicine and impacting global human longevity.
For more information, visit www.diagen.ai.